Table 2 A comparison of HNC patients derived tumouroids culture conditions.
From: Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges
Clevers and Driehuis’s method | Kijima and Nakagawa’s method | |
|---|---|---|
Base media | Advanced DMEM/ F12 (includes GlutaMAX, HEPES, Penicillin–streptomycin) | Advanced DMEM/F12 (includes GlutaMAX, HEPES, Gentamicin, and Antibiotic-Antimycotic) |
Primocin | 100 μg/mL | |
Gentamicin | 10 µg/mL | |
Antibiotic-Antimycotic | x1 | |
RN conditioned medium (that includes R-spondin and Noggin) | 2% | |
B27 supplement | 1 | x1 |
N2 (x) | x1 | |
R-spondin (% v/v for CM or ng/mL for rec) | 4% v/v | 50 ng/mL |
Noggin (% v/v for CM or ng/mL for rec) | 4% v/v | |
N-acetyl-l-cysteine (NAC) (mM) | 1.25 | 1 ng/mL |
Nicotinamide (NIC) (mM) | 10 mM | |
Human Epidermal growth factor (EGF) (ng/mL) | 50 ng/mL | |
3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide (A83-01) (μM) | 0.5 μM | |
Human Fibroblast Growth Factor 10 (FGF10) (ng/mL) | 10 ng/mL | |
Human Fibroblast Growth Factor 2 (FGF2) (ng/mL) | 5 ng/mL | |
Prostaglandin E2 (μM) | 1 μM | |
Forskolin (μM) | 1 μM | |
CHIR 99021 (C22H18Cl2N8) (μM) | 3 μM | |
Rho-associated kinase (ROCK) inhibitor Y-27632 (μM) | 10 μM | 10 μM |
